Delivery Order SPE2DB25D3108-SPE2DB25FPDJX
- Not listed
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical distributor. The $10,358.80 order is for the supply of Mekinist 0.5 mg tablets in support of military treatment programs and facilities. AmerisourceBergen Drug Corp holds an indefinite delivery contract with DLA with a potential value of $999,999,999.00 through December 31, 2025, which serves as...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $9,670.51, is for the delivery of the prescription drug Mekinist 2 mg tablets. The contract is a firm fixed-price, non-set-aside award with a completion date of May 21, 2025. AmerisourceBergen Drug Corp, the prime contractor, is a for-profit organization headquartered in Conshohocken, Pennsylvania. The contract is part of a...
- This is a $57,276.83 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of the medication MEKINIST 2 MG TABLET UU 30S, with a period of performance through May 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $9,670.51, is for the delivery of Mekinist 2 mg tablets, a prescription medication. The delivery order has a firm fixed price and an ultimate completion date of May 23, 2025. This award is not associated with a set-aside program and is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Mekinist 0.5 mg tablets. The contract, which is not set aside, has a ceiling value of $2,589.70 and a completion date of August 9, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts to provide a wide range of essential medical commodities, including specialty medications, branded and generic drugs, vaccines, and...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is a delivery order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC). The $18,371.32 fixed-price award is for the delivery of 4,566,462,969 units of the drug MEKINIST 2 MG Tablet with a completion date of December 10, 2024. The contract has no set-aside designation, indicating open competition. AmerisourceBergen is the prime contractor, and the award is...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,878.79 Firm Fixed Price Delivery Order contract provides the DLA with Mekinist 2 mg tablets, a medication used to treat certain types of cancer. The contract has an ultimate completion date of July 16, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The $6,064.14 firm fixed price order is for the supply of Mekinist 0.05 mg/ml solution, a prescription medication. This order is part of a larger, indefinite delivery contract (IDC) between DLA and AmerisourceBergen Drug Corp, which has a potential value of...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide MEKINIST 2 MG TABLET UU 30S, a pharmaceutical product, with a potential value of $8,878.79. The order has a completion date of March 18, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with the Defense Logistics Agency valued at up to $999,999,999.00 through December 31, 2025,...
- This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the supply of the prescription drug Mekinist 0.5 mg tablet, with a ceiling value of $8,552.49 and a period of performance through May 23, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDJXDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,403.32 to AmerisourceBergen Drug Corp for the supply of Mekinist 0.5 mg tablets (30-count units). The contract, awarded July 21, 2025, carries a firm fixed price and is scheduled for completion by August 11, 2025. This is a non-set-aside, competitively awarded delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle that runs through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mekinist is a targeted cancer therapy used in oncological treatments, and this delivery order reflects DLA's ongoing need to maintain pharmaceutical inventories to support military healthcare systems and veteran medical programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, regularly fulfills federal medical procurement requirements through its extensive IDC with the DLA, enabling supply of brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. The company's federal contract portfolio demonstrates its capability to meet competitive procurement standards across a wide range of medical supply needs serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 7/21/25 |